drugset / Trial / NCT03809702

Efficacy of Pregabalin for the Treatment of Acute Herpetic Neuralgia

NCT03809702

RandomizedParallel-groupDouble-blindTreatment

Summary

All eligible Herpes Zoster patients will be randomized into two groups. Group 1 will be the treatment group receiving Pregabalin 75 mg twice daily for 4 weeks in addition to other routine treatment. Whereas, group 2 will be the control group receiving all routine treatment similar to group 1 except Pregabalin. Instead control group will receive Placebo.

Timeline

Start
2018-07-15
Primary completion
2019-09-20
Completion
2019-12-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Pregabalin Small molecule 75 mg Oral

Indications